PEPTIDE MEDIATED IMMUNOTHERAPY FOR AUTOIMMUNE DISEASE

自身免疫性疾病的免疫特异性无毒治疗进展 是这项工作的一个主要目标。该项目是基于示范， 实验性自身免疫性脑脊髓炎（EAE），这是可能的， 用单克隆抗体（mAb）预防或逆转麻痹性疾病 特异于T细胞受体（TcR）V区或II类主要 组织相容性复合体（MHC）分子，呈递髓鞘碱性 蛋白（MBP）。此外，可以设计非免疫原性肽 阻断致脑炎髓鞘片段与MHC结合的能力。 在该项目中，进一步开发用于治疗 将进行EAE。不仅阻断MHC，而且不结合 将检测TcR。最后，用V-DJ和V-J进行分子疫苗接种 来自致脑炎性T细胞的TcR序列的肽将用于 治疗EAE。这些使用治疗性肽的方法可能导致 自身免疫性疾病药物的合理设计。

The development of non-toxic, immunospecific therapy for autoimmune disease is a major goal of this work. The project is based on the demonstration in experimental autoimmune encephalomyelitis (EAE) that it is possible to prevent or reverse paralytic disease with monoclonal antibodies (mAb) specific for the T cell receptor (TcR) V region or for the class II major histocompatibility complex (MHC) molecule that presents myelin basic protein (MBP). Further, it is possible to design non-immunogenic peptides that block the ability of encephalitogenic myelin fragments to bind to MHC. In this project further development of blocking peptides for treatment of EAE will be undertaken. Peptides that not only block MHC but do not bind TcR will be tested. Finally, molecular vaccination with V-DJ and V-J peptides from the TcR sequence of encephalitogenic T cells will be used to treat EAE. These approaches using therapeutic peptides could lead to the rational design of drugs for autoimmune disease.